MarketPulse

Aquestive Therapeutics

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Class Action Over Anaphylm FDA Approval Claims

Class action lawsuit filed against $AQST alleging securities fraud over false FDA timeline statements and concealed safety risks for Anaphylm drug.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Faces Securities Fraud Lawsuit Over FDA Approval Claims

Class action lawsuit filed against $AQST alleging executives made false statements about Anaphylm FDA approval timeline and concealed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Eos Energy Shares Crater 39% Amid Production Woes, Triggering Class Action Lawsuit

Eos Energy stock plummeted 39.44% after missing earnings targets due to production and quality control issues, prompting Pomerantz Law Firm to file securities fraud class action lawsuit.
EOSEAQSTNKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

Aquestive Therapeutics Faces Securities Lawsuit After Anaphylm FDA Setback Triggers 37% Stock Plunge

Aquestive Therapeutics faces securities lawsuit after FDA Anaphylm deficiency notice triggers 37% stock decline from $6.21 to $3.91 on January 9, 2026.
AQSTstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Franklin BSP Realty Trust Faces Securities Lawsuit; Lead Plaintiff Deadline Set for April 2026

Rosen Law Firm files securities class action against Franklin BSP Realty Trust ($FBRT) over alleged misstatements on dividends; April 2026 deadline for lead plaintiff participation.
FBRTFBRTpEIBRXAQSTinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aquestive Therapeutics Hit With Securities Fraud Suit Over Anaphylm FDA Timeline Claims

Class action lawsuit filed against Aquestive Therapeutics alleging securities fraud related to Anaphylm FDA approval timeline and undisclosed human factors risks.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Lawsuit Filed Against Aquestive Over Anaphylm Drug Application Misstatements

Rosen Law Firm seeks lead plaintiffs in securities lawsuit against Aquestive Therapeutics over alleged false statements regarding Anaphylm drug application.
AQSTsecurities class actionlead plaintiff